Overweight Clinical Trial
— MATISSEOfficial title:
Effect of High-Intensity Interval Training and Moderate-Intensity Continuous Training on Abdominal Fat Mass and Energy Substrates Utilization in Postmenopausal Women
Postmenopausal women, as men, are more prone to central or android obesity than premenopausal
women. Abdominal fat mass accumulation is associated with an increase of cardiovascular
disease (CVD) risk.
Most exercise programs designed for weight loss have focused on about 30 min several times
per week of moderate intensity continuous training (MICT). Disappointingly, such exercise
programs have led to either none or low fat loss. Accumulating evidence suggests that high
intensity interval training (HIIT) should be an effective exercise protocol for reducing body
fat of overweight individuals, especially at the abdominal level.
Resistance Training (RT) is associated with increased muscle mass and strength gain in main
muscles groups. Thus, RT seems to be an interesting strategy to fight against deconditioning
and autonomy loss with age. Development of muscle mass enhances resting metabolism rate.
Thus, RT could raise daily energy expenditure ie. substrates' oxidation including lipids.
The aim of our study was to compare the effects of a 12-week moderate intensity continuous
training (MICT) program with high intensity interval training (HIIT) program combined or not
with a resistance training (RT) program on total abdominal and visceral fat mass and
substrate utilization in postmenopausal women.
It is hypothesized that HIIT compared to MICT program would result in significantly greater
whole body and regional fat mass losses (abdominal and visceral) and would improve lipid
oxidation at rest and during prolonged moderate exercise. It is also hypothesized that HIIT
associated with RT could be the best strategy to reduce fat mass.
Status | Completed |
Enrollment | 36 |
Est. completion date | June 8, 2018 |
Est. primary completion date | June 8, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 55 Years to 82 Years |
Eligibility |
Inclusion Criteria: - Postmenopausal women (55- 82 years) - BMI = 25 and < 40 - Able to follow an exercise protocol - Eating behavior and physical activity stable since at least 3 month Exclusion Criteria: - Subject not able to perform exercise after medical examination - Subject not able to perform bicycle exercise (pains) - Chronic infection - Use of ß-blocker - Medical treatment that could interfere with the different outcome measures - Hormonal Replacement Therapy (HRT) - Regular consumption of alcohol - Refusal to sign the consent form |
Country | Name | City | State |
---|---|---|---|
France | CREPS Vichy Auvergne | Bellerive-sur-Allier |
Lead Sponsor | Collaborator |
---|---|
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques | CREPS Vichy Auvergne, University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline abdominal fat mass (g) after 3 months of training (T3-T0/T0 x 100) | Total abdominal fat mass will be measured in all patients using DEXA based on the methodology of Martin and Jensen (1991; L1-L2 to pubic rami) before (baseline, T0) and after 3 months of training (T3). | Baseline T0, 3 months after protocol starting | |
Secondary | Lipids oxidation evaluated by gas exchange measurements | Evolution of lipids oxidation at rest and during prolonged moderate intensity (40min, 50% of VO2max) using an automated gas analysis system. Carbon dioxide (CO2) production and oxygen consumption (CO2) are expressed in L/min. Respiratory exchange ratio is the ratio between CO2 production and O2 consumption (RER = VCO2/VO2). | 1 week, 3 months after protocol starting | |
Secondary | Visceral fat mass | Change from baseline in visceral fat mass (g) (estimated from DEXA) | Baseline T0, 3 months after protocol starting | |
Secondary | Total fat mass | Change from baseline in total fat mass (g) (determined from DEXA) | Baseline T0, 3 months after protocol starting | |
Secondary | Fat-free mass | Change from baseline in total fat-free mass (g) (determined from DEXA) | Baseline T0, 3 months after protocol starting | |
Secondary | Plasma HbA1c | Change from baseline in plasma HbA1c | Baseline T0, 3 months after protocol starting | |
Secondary | Glucose level | Change from baseline in plasma glucose measurement | Baseline T0, 3 months after protocol starting | |
Secondary | Plasma triglycerides | Change from baseline in plasma triglycerides | Baseline T0, 3 months after protocol starting | |
Secondary | Plasma total cholesterol | Change from baseline in total cholesterol | Baseline T0, 3 months after protocol starting | |
Secondary | Plasma HDL-cholesterol | Change from baseline in HDL-cholesterol | Baseline T0, 3 months after protocol starting | |
Secondary | Plasma LDL-cholesterol | Change from baseline in LDL-cholesterol | Baseline T0, 3 months after protocol starting | |
Secondary | Insulin level | Change from baseline in plasma insulin measurement | Baseline T0, 3 months after protocol starting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 |